QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, W. Articles by Surratt, C. K. Search for Related Content PubMed PubMed Citation Articles by Wang, W. Articles by Surratt, C. K.

Dissociation of High-Affinity Cocaine Analog Binding and Dopamine Uptake Inhibition at the Dopamine Transporter

Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York (W.W., H.S., C.K.S.); Vollum Institute, Oregon Health and Science University, Portland, Oregon (M.S.S.); Medications Discovery Research Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland (M.K.K.); Department of Pharmacology and Toxicology, Duquesne University, Pittsburgh, Pennsylvania (O.T.U., C.K.S.)

Cocaine initiates its euphoric effects by binding to the dopamine transporter (DAT), blocking uptake of synaptic dopamine. It has been hypothesized that the DAT transmembrane aspartic acid residue D79 forms an ionic interaction with charged nitrogen atoms in both dopamine and cocaine. We examined the consequences of novel and previously studied mutations of the D79 residue on DAT uptake of [³H]dopamine, DAT binding of the cocaine analog [³H]WIN 35,428, and drug inhibition of each process, all under identical conditions. The rat D79E DAT mutation decreased dopamine uptake V_max by 7-fold and decreased dopamine turnover by 4-fold. Wild-type DAT displayed near-perfect agreement in the uptake and binding inhibition potencies for substrates, but cocaine and other nonsubstrate inhibitor drugs were 3-fold less potent in uptake than in binding assays. Apparent affinities for substrates were unaffected by the D79E mutation unless the catechol moiety was modified. Strikingly, potencies for nonsubstrate inhibitors in uptake and binding assays matched for D79E DAT, because of a 3-fold lowering of binding affinities relative to WT DAT. The present findings reveal a complex role for D79 in determining substrate specificity and high-affinity binding of DAT inhibitors. We propose that at least two discrete inhibitor-binding DAT conformations or populations exist and that the DAT conformation/population responsible for inhibitor high-affinity binding is less responsible for dopamine uptake. The findings may be extensible to other psychostimulants and antidepressants that display discrepancies between binding affinity and monoamine uptake inhibition potency and may be relevant to development of a long-sought "cocaine antagonist".

Address correspondence to: Dr. Christopher K. Surratt, Division of Pharmaceutical Sciences, Duquesne University, 453 Mellon Hall, 600 Forbes Avenue, Pittsburgh, PA 15282. E-mail: surratt{at}duq.edu.

This article has been cited by other articles:

				O. T. Ukairo, C. D. Bondi, A. H. Newman, S. S. Kulkarni, A. P. Kozikowski, S. Pan, and C. K. Surratt Recognition of Benztropine by the Dopamine Transporter (DAT) Differs from That of the Classical Dopamine Uptake Inhibitors Cocaine, Methylphenidate, and Mazindol as a Function of a DAT Transmembrane 1 Aspartic Acid Residue J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 575 - 583. [Abstract] [Full Text] [PDF]